The future of obesity treatment looks highly promising with the development of next generation therapies. There are currently 79 clinical stage programmes across at least 41 unique mechanisms of ...
Recent data from an Amgen obesity-drug trial only reinforced investors' impressions that Eli Lilly and Novo Nordisk have a prohibitive head start, thanks, in particular, to a new generation of Lilly ...
GlobalData on MSN10h
Four oral GLP-1R products in Phase III trials as race intensifiesGLP-1R injectable drugs are effective in treating obesity, but their success points to a gap in the market: oral alternatives.
The price of Wegovy, the diabetes control drug's glamorous anti-obesity sibling, may also be falling, according to a Health ...
Novo Nordisk A/S (NYSE:NVO) is a Danish multinational pharmaceutical company that specializes in the discovery, development, ...
After losing and regaining the same 20-plus pounds more times than she could count, Anita Blanchard concluded that diets ...
Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.
The biotech industry can be volatile even for relatively large companies. Amgen ( AMGN 1.00%), one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the company's ...
Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...
A new study finds people who take weight-loss drugs also cut back on alcohol consumption. Researchers think the drugs could ...
It's uncertain whether the Biden administration proposal to cover obesity drugs in Medicare and Medicaid will survive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback